Connect Biopharma Holdings Future Growth
Future criteria checks 0/6
Connect Biopharma Holdings's earnings are forecast to decline at 5.2% per annum while its annual revenue is expected to grow at 6.4% per year. EPS is expected to decline by 2% per annum.
Key information
-5.2%
Earnings growth rate
-2.0%
EPS growth rate
Biotechs earnings growth | 24.4% |
Revenue growth rate | 6.4% |
Future return on equity | n/a |
Analyst coverage | Low |
Last updated | 13 Jun 2024 |
Recent future growth updates
Recent updates
Companies Like Connect Biopharma Holdings (NASDAQ:CNTB) Are In A Position To Invest In Growth
Mar 07Is Connect Biopharma Holdings (NASDAQ:CNTB) In A Good Position To Invest In Growth?
Sep 19Will Connect Biopharma Holdings (NASDAQ:CNTB) Spend Its Cash Wisely?
Mar 29Is Connect Biopharma Holdings (NASDAQ:CNTB) In A Good Position To Deliver On Growth Plans?
Dec 14Market Appears To Relegate Connect Biopharma To A Long-Term Hold
Oct 10Connect Biopharma Is A Sleeper Heading Into October Data Readout
Sep 26Connect Biopharma reports 1H results
Sep 13We're Keeping An Eye On Connect Biopharma Holdings' (NASDAQ:CNTB) Cash Burn Rate
Aug 12We're Keeping An Eye On Connect Biopharma Holdings' (NASDAQ:CNTB) Cash Burn Rate
Apr 29Connect Biopharma's Latest Dermatitis Drug Update Fails To Pump Up Shares
Jan 12We're Hopeful That Connect Biopharma Holdings (NASDAQ:CNTB) Will Use Its Cash Wisely
Jan 01Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 29 | -78 | -57 | N/A | 2 |
12/31/2025 | 35 | -61 | -44 | N/A | 2 |
12/31/2024 | 158 | -30 | 87 | N/A | 1 |
12/31/2023 | N/A | -60 | -48 | -48 | N/A |
9/30/2023 | N/A | -75 | -67 | -65 | N/A |
6/30/2023 | N/A | -84 | -79 | -76 | N/A |
3/31/2023 | N/A | -102 | -93 | -90 | N/A |
12/31/2022 | N/A | -118 | -106 | -102 | N/A |
9/30/2022 | N/A | -131 | -107 | -103 | N/A |
6/30/2022 | N/A | -114 | -97 | -95 | N/A |
3/31/2022 | N/A | -163 | -96 | -93 | N/A |
1/1/2022 | N/A | -202 | -88 | -84 | N/A |
9/30/2021 | N/A | -229 | -76 | -71 | N/A |
6/30/2021 | N/A | -255 | -63 | -57 | N/A |
3/31/2021 | N/A | -185 | -45 | -41 | N/A |
12/31/2020 | N/A | -119 | -28 | -26 | N/A |
12/31/2019 | N/A | -24 | -13 | -13 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: CNTB is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: CNTB is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: CNTB is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: CNTB's revenue (6.4% per year) is forecast to grow slower than the US market (8.6% per year).
High Growth Revenue: CNTB's revenue (6.4% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if CNTB's Return on Equity is forecast to be high in 3 years time